Personalized medicine via Advanced and Integrated Radiomics (AIRad) RCSO ISNet
The objective of the project is twofold: (i) develop three-tiered software architectures to enable image-based personalized medicine at the national level using established radiomics practices and (ii) inject latest research outcomes of the MedGIFT group in terms of Quantitative Imaging Biomarkers (QIB) into the upcoming radiomics pipeline sponsored by the Swiss Personalized Health Network (SPHN).
Over the past five years, ‘radiomics’ has become a buzz word in all imaging departments of modern hospitals. It consists of using Artificial Intelligence (AI) to leverage the wealth of modern radiological and molecular imaging to predict optimal treatment options and prognosis based on personal patient characteristics. While being complementary to existing personalized medicine practices such as genomics and pathomics, radiomics has the advantage of being non-invasive and yields a comprehensive overview of the diseased tissue.
The MedGIFT group has recently been mandated by the SPHN to deploy a radiomics pipeline for clinical studies in the university hospitals of Switzerland. During the past fifteen years, the MedGIFT group developed and validated several innovative QIBs that are addressing shortcomings of the state-of-the-art in radiomics.
The primary goal of AIRad is to develop three-tiered software architectures to enable web-based front ends, persistence of QIBs, and portability of the radiomics services developed in the context of the SPHN funding. Graphical and non-graphical web interfaces will be developed to allow performing Radiomics operations via the Software as a Service (SaaS) scheme. This will make the radiomics services available beyond the Swiss level to the international research community and pave the way for Horizon Europe and other international project submissions. The second objective of this project is to inject the most promising QIBs developed by the MedGIFT group in the upcoming SPHN radiomics pipeline. This will boost the visibility of our most notable recent research achievements and reinforce our leading role in the field for future inclusion in best project consortiums.